Published in J Exp Med on August 01, 1977
Isohemagglutinins of graft origin after ABO-unmatched liver transplantation. N Engl J Med (1984) 2.25
Synthesis of human plasminogen by the liver. Science (1980) 1.27
Tissue-specific and ubiquitous expression patterns from alternative promoters of human genes. PLoS One (2010) 1.04
Complement-subcomponent-C1-inhibitor synthesis by human monocytes. Biochem J (1985) 0.99
Cyclic nucleotides and their relationship to complement-component-C2 synthesis by human monocytes. Biochem J (1984) 0.99
Modulation of complement membrane attack by local C7 synthesis. Clin Exp Immunol (2000) 0.83
Biosynthesis of complement components by cultured rat hepatocytes. Biochem J (1985) 0.75
Human C'3: evidence for the liver as the primary site of synthesis. Science (1969) 4.17
Rheumatoid arthritis. Biosynthesis of complement proteins by synovial tissues. N Engl J Med (1974) 1.88
Formation of C'-6 by rabbit liver tissue in vitro. Immunology (1968) 1.24
Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet (1979) 12.29
Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet (1979) 6.10
Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89
The demonstration in human serum of "conglutinogen-activating factor" and its effect on the third component of complement. J Immunol (1968) 5.40
Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation (1979) 5.12
Reactive lysis: the complement-mediated lysis of unsensitized cells. II. The characterization of activated reactor as C56 and the participation of C8 and C9. J Exp Med (1970) 4.92
Liver transplantation in man. I. Observations on technique and organization in five cases. Br Med J (1968) 4.38
Reactive lysis: the complement-mediated lysis of unsensitized cells. I. The characterization of the indicator factor and its identification as C7. J Exp Med (1970) 4.29
CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells. J Exp Med (1989) 4.19
AIDS--an immunologic reevaluation. N Engl J Med (1984) 3.53
The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology (1973) 3.41
Conglutinin and immunoconglutinins. Adv Immunol (1967) 3.16
Improved survival after orthotopic liver grafting. Br Med J (Clin Res Ed) (1981) 3.09
Liver transplantation for malignant disease. Results in 93 consecutive patients. Ann Surg (1988) 3.04
Use of partial cardiopulmonary bypass during the anhepatic phase of orthotopic liver grafting. Lancet (1979) 2.98
Haemolytic diffusion plate assays for factors B and D of the alternative pathway of complement activation. Immunochemistry (1976) 2.89
Deficiency of C3 inactivator in man. J Immunol (1971) 2.86
A new technique for biliary drainage in orthotopic liver transplantation utilizing the gall bladder as a pedicle graft conduit between the donor and recipient common bile ducts. Ann Surg (1976) 2.86
Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci U S A (1972) 2.84
Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest (1974) 2.81
Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers. Immunology (1990) 2.77
Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) (1981) 2.67
The immunological specificity of a macrophage inhibition factor. Immunology (1970) 2.66
Complement studies in membrano-proliferative glomerulonephritis. Clin Exp Immunol (1972) 2.60
Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol (2000) 2.59
Prolonged survival of pig orthotopic heart grafts treated with cyclosporin A. Lancet (1978) 2.57
Liver transplantation. Curr Probl Surg (1979) 2.57
Rapamycin for immunosuppression in organ allografting. Lancet (1989) 2.51
The physiological breakdown of the third component of human complement. Mol Immunol (1980) 2.50
Orthotopic liver transplantation: the first 60 patients. Br Med J (1977) 2.50
Soluble HLA antigens in the circulation of liver graft recipients. Transplantation (1989) 2.48
A surgical experience with five hundred thirty liver transplants in the rat. Surgery (1983) 2.48
Some personal observations on the university department of surgery. Ann R Coll Surg Engl (1977) 2.46
Reaction mechanism of the alternative pathway of complement fixation. Lancet (1973) 2.38
Type C retrovirus inactivation by human complement is determined by both the viral genome and the producer cell. J Virol (1994) 2.36
Identification of an anti-monocyte monoclonal antibody that is specific for membrane complement receptor type one (CR1). Eur J Immunol (1984) 2.20
The purification of specific antibody as F(ab')2 by the pepsin digestion of antigen-antibody precipitates, and its application to immunoglobulin and complement antigens. Immunochemistry (1971) 2.16
Prolonged survival of liver transplants in the pig. Br Med J (1967) 2.14
Cyclosporine: five years' experience in cadaveric renal transplantation. N Engl J Med (1984) 2.10
Simple hypothermic preservation for transporting human livers long distances for transplantation. Report of 12 cases. Transplantation (1977) 2.08
Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies. J Exp Med (1982) 2.04
Hereditary angio-oedema: a review with particular reference to pathogenesis and treatment. Clin Allergy (1971) 2.00
Liver transplantation in man: the frequency of rejection, biliary tract complications, and recurrence of malignancy based on an analysis of 26 cases. Gastroenterology (1973) 1.99
A sedimentation pattern technique for measuring conglutination: its application to demonstrating immunoconglutinins to C'4. Immunology (1966) 1.95
Transplant surgery: current status. Br J Surg (1980) 1.95
The treatment of systemic lupus erythematosus (SLE) in NZB/W F1 hybrid mice; studies with recombinant murine DNase and with dexamethasone. Clin Exp Immunol (1996) 1.94
Cyclosporin A: preliminary observations in dogs with pancreatic duodenal allografts and patients with cadaveric renal transplants. Transplant Proc (1979) 1.94
The influence of C3b inactivator (KAF) concentration on the ability of serum to support complement activation. Clin Exp Immunol (1975) 1.93
Role of C3b in the breakdown of C3 in hypocomplementaemic mesangiocapillary glomerulonephritis. Lancet (1973) 1.93
Bile composition and bile cast formation after transplantation of the liver in man. Transplantation (1975) 1.92
The preparation and properties of alexinated intermediates that react with conglutinin. I. Guinea-pig complement. Immunology (1966) 1.92
Three rat monoclonal antibodies to human C3. Immunology (1980) 1.91
Liver transplantation in 100 children: Cambridge and King's College Hospital series. BMJ (1992) 1.90
Liver transplantation in patients with alcoholic cirrhosis: selection criteria and rates of survival and relapse. BMJ (1990) 1.88
The preparation and properties of alexinated intermediates that react with conglutinin. II. Equine, rabbit and human complement. Immunology (1966) 1.88
Immunoglobulin heavy chain genes in humans are located on chromosome. Ann Hum Genet (1981) 1.85
Hypercalcemia and increased parathyroid-hormone activity in a primary hepatoma. Studies before and after hepatic transplantation. N Engl J Med (1970) 1.83
Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. Lab Invest (1991) 1.79
Family studies of erythrocyte complement receptor type 1 levels: reduced levels in patients with SLE are acquired, not inherited. Clin Exp Immunol (1985) 1.76
Gastrointestinal complications after renal transplantation. Lancet (1971) 1.71
Conglutinin binding polyethylene glycol precipitation assay for immune complexes. Clin Exp Immunol (1979) 1.71
Observations of orthotopic liver transplantation in the pig. Br Med J (1967) 1.69
The effect of antibody isotype and antigenic epitope density on the complement-fixing activity of immune complexes: a systematic study using chimaeric anti-NIP antibodies with human Fc regions. Clin Exp Immunol (1991) 1.68
Evidence for an immune response to HLA class I antigens in the vanishing-bileduct syndrome after liver transplantation. Lancet (1987) 1.68
Liver transplantation in man. II. A report of two orthotopic liver transplants in adult recipients. Br Med J (1968) 1.68
Liver transplantation. Transplant Rev (1969) 1.67
Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. Am J Transplant (2008) 1.67
Combined mediastinal and retroperitoneal fibrosis. Lancet (1966) 1.66
Outcome of HIV infection in transplant patient on cyclosporin. Lancet (1991) 1.66
Recurrence of primary biliary cirrhosis after liver transplantation. N Engl J Med (1982) 1.64
Hereditary angio-oedema treated with E-aminocaproic acid. Br J Dermatol (1969) 1.64
Identification of Ss protein as murine C4. Nature (1975) 1.63
Membrane defence against complement lysis: the structure and biological properties of CD59. Immunol Res (1993) 1.63
Deficiency of factor B of the complement system in sickle cell anaemia. Br Med J (1976) 1.61
Cyclosporin A stimulates proliferation of the liver cells after partial hepatectomy in rats. Surg Gynecol Obstet (1988) 1.60
The in vivo behaviour of complement-coated red cells: studies in C6-deficient, C3-depleted and normal rabbits. Clin Exp Immunol (1970) 1.60
The behaviour of complement and platelets in lethal endotoxin shock in rabbits. Int Arch Allergy Appl Immunol (1973) 1.60
Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet (1988) 1.60
The relationship of desoxyribonuclease inhibitor levels in human sera to the occurrence of antinuclear antibodies. Clin Exp Immunol (1968) 1.58
Structural relationship and complement fixing activity of sheep and other ruminant immunoglobulin G subclasses. Nature (1969) 1.57
Differentiation between specific and non-specific hepatitis C antibodies in chronic liver disease. Lancet (1990) 1.57
Detection of IgA antibodies by the red cell linked antigen-antiglobulin reaction: antibodies in the sera of infants to milk proteins. Int Arch Allergy Appl Immunol (1965) 1.56
Administration of heparin and antibiotic prophylaxis. Br J Surg (1994) 1.55
Complement genetics in relation to HLA. Br Med Bull (1978) 1.55
Cellular immune response during rejection of a liver transplant in man. Nature (1969) 1.55
Initiation of complement activation. Springer Semin Immunopathol (1984) 1.54
Observations on preservation, bile drainage and rejection in 64 human orthotopic liver allografts. Ann Surg (1977) 1.53
The effect of liver transplantation in a 13-year-old boy with erythropoietic protoporphyria. Transplantation (1988) 1.51
A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol (1977) 1.50
The immunogloblin nature of nephritic factor (NeF). Clin Exp Immunol (1978) 1.47
The prevention of renal impairment in patients undergoing orthotopic liver grafting by infusion of low dose dopamine. Anaesthesia (1987) 1.47
Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. Br Med J (1978) 1.46
The mechanism of action of the C3b inactivator (conglutinogen-activating factor) on its naturally occurring substrate, the major fragment of the third component of complement (C3b). J Exp Med (1975) 1.43